<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:120349332;
mso-list-template-ids:747169996;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:274601618;
mso-list-template-ids:903796176;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2
{mso-list-id:1496456523;
mso-list-template-ids:-201838136;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:1830293111;
mso-list-template-ids:845600520;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">FSU Council on Research and Creativity</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/eieg/" title="https://www.research.fsu.edu/research-offices/ord/crc/programs/eieg/">Equipment & Infrastructure Enhancement
(EIEG) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-review deadline: </span></b><span style="font-size:12.0pt;font-family:Palatino"> February 14, 2022, 4:59 p.m.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 24, 2022. <span style="color:red">Med-RA deadline to receive draft documents: February 14.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/mds/">Multidisciplinary Support (MDS) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-review deadline: </span></b><span style="font-size:12.0pt;font-family:Palatino">January 24, 2021, 4:59 p.m.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 3, 2022. <span style="color:red">Med-RA deadline to receive draft documents: January 24.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/pg/">Planning Grant (PG) Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-review deadline: </span></b><span style="font-size:12.0pt;font-family:Palatino">February 7, 2022, 4:59 p.m.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 17, 2022. <span style="color:red">Med-RA deadline to receive draft documents: February 7.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/ord/crc/programs/sgp/">Small Grants Program (SGP)</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-review deadline: </span></b><span style="font-size:12.0pt;font-family:Palatino"> February 28, 2022, 4:59 p.m.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 10, 2022. <span style="color:red">Med-RA deadline to receive draft documents: February 28.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-030.html">Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01
– Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human clinical testing of gene-based or
transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement is to accelerate the development of a promising clinical candidate
with robust biological rationale and demonstrated proof of concept data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 9, 2022; June 9, 2022; October 8, 2022; February 9, 2023; June 9, 2023; October 10, 2023; February 8, 2024; and June 7, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for February 9, 2022 due date: January 27.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-21-001.html">Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement encourages grant applications to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes.
Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 11, 2022; January 26, 2023; and January 26, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for February 11, 2022 due date: January 31.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Exploratory/Developmental Bioengineering Research Grants (EBRG)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-090.html">R21 Clinical Trial Not Allowed</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-19-150.html" target="_blank">R21 Clinical Trial Optional</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these engineering-oriented funding opportunity announcements is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to
demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery,
or accessibility<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires January 8, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for February 16, 2022 standard date: February 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-007.html" target="_blank">Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement is to announce the availability
of funding to demonstrate and enhance the utility of selected Common Fund (<a href="https://commonfund.nih.gov/">https://commonfund.nih.gov/</a>) data sets, including generating hypotheses and catalyzing discoveries. Award recipients are asked to provide feedback
on the utility of the Common Fund data resources.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 18, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: February 7.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://jlabs.jnjinnovation.com/quickfire-challenges/food-allergy-prevention-quickfire-challenge" target="_blank">Johnson & Johnson QuickFire Challenge: Food Allergy Prevention</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Johnson & Johnson Innovation LLC and the Healthy Baby Initiative within Janssen Research & Development’s World Without Disease Accelerator in partnership with the Food Allergy Fund, has
launched the Food Allergy Prevention QuickFire Challenge. Food allergies are a growing public health problem, and for many affected individuals, food allergy begins early in life and persists as a lifelong condition. However, a growing body of work provides
insights into potential pathways to reduce the risk of developing food allergies. For example, research points to a window of opportunity in the early years of a child’s life to reduce the risk of food allergies through the early and ongoing ingestion of allergenic
foods; data suggest a healthy gut microbiome plays a critical role in decreasing risk; and progress is being made in identifying recognizable risk factors associated with increased likelihood of developing a food allergy, including atopic dermatitis, antibiotic
exposure, C-section delivery, and/or a gut microbiome dysbiosis. Through the challenge, the innovator(s) with the best novel methods, products, or technologies have the potential to receive grant funding from a total pool of $150,000, in increments of $75,000,
$50,000, or $25,000; access to the global Johnson & Johnson Innovation – JLABS network; and mentorship from experts across the Johnson & Johnson Family of Companies. Submissions should aim to address one or more of the following focus areas:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo3"><b><span style="font-size:12.0pt;font-family:Palatino">Risk detection</span></b><span style="font-size:12.0pt;font-family:Palatino"> including connected devices for both point-of-care and at-home prognostics/diagnostics.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><b><span style="font-size:12.0pt;font-family:Palatino">Interventions and treatments</span></b><span style="font-size:12.0pt;font-family:Palatino"> including preventive therapeutics and health technologies<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo3"><b><span style="font-size:12.0pt;font-family:Palatino">Community platforms</span></b><span style="font-size:12.0pt;font-family:Palatino"> with the potential to establish connectivity, monitor data, educate
the public with a specific focus on socioeconomic disparities, and assist communities<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due February 18, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: February 7.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.research.fsu.edu/research-offices/oc/gap/">FSU GAP Commercialization Investment Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The FSU Office of Commercialization is currently accepting applications for the Spring 2022 GAP Commercialization Investment competition, sponsored by the FSU Office of Research. The FSURF
GAP Program is designed to support enhancements of inventions or other original works that have been disclosed to FSU. It funds projects that will quickly improve the odds that current research leads to public availability of a new product or service.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Pre-proposal due February 25.
<span style="color:red">Med-RA deadline to receive draft documents: February 14.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-034.html" target="_blank">Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical
Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically,
the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system, or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no
abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop
small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the
body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other
headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, orofacial pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions
or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 2, 2022; June 2, 2022; October 2, 2022; February 2, 2023; June 2, 2023; October 4, 2023; February 2, 2024; June 4, 2024; and October 2, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for March 2, 2022 due date: February 17.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-038.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-037.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcement (FOAs) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging
data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. These FOAs encourage the
analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and
resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data
collection is not allowed for applications in response to these FOAs.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 4, 2022; August 5, 2022; November 15, 2022; March 7, 2023; August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; and November 15, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for March 4, 2022 due date: February 21.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R61 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-360.html">R61: Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related
Cognitive Decline</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 4, 2022; June 17, 2022; October 18, 2022; February 17, 2023; June 19, 2023; October 18, 2023; February 20, 2024; June 18, 2024; and October 18, 2024.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-359.html">R01: Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and
Age-Related Cognitive Decline</a><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March</span></b><span style="font-size:12.0pt;font-family:Palatino">
<b>4, 2022; June 5, 2022; October 5, 2022; February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024; and October 5, 2024.</b><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising
pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer’s disease and Alzheimer’s disease-related dementias across the spectrum from pre-symptomatic to more
severe stages of disease, and 2) stimulate studies to enhance trial design and methods.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for March 4, 2022 due date: February 21.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21 / R01 – Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-045.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-044.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements is to develop new, exploratory methods, approaches, and/or tools to apply to existing data streams (e.g., electronic health records,
syndromic surveillance, claims data, registry data, pharmacy dispensing, and mortality records) that could provide novel insights into the dynamics of opioid and prescription drugs misuse, addiction, recovery, relapse, and recovery to facilitate rapid understanding
of the opioid epidemic for prevention and treatment or to develop methods for small area estimation that inform decisions of local (e.g., substate) jurisdictions. They will emphasize approaches that shorten the lags between data capture and data availability
so the data is available real-time or near real-time to provide actionable insights, and methods and tools that improve efficiency and practical use of surveillance, clinical or other relevant data that may allow for faster or better localized responses or
better allocation of resources to address the opioid epidemic.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 10, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: February 28.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-046.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The National Institutes of Health (NIH) intends to establish a Harm Reduction Network consisting of several research projects and a single Coordination Center. The goal of this network
is to increase our understanding of the effectiveness, implementation, and impact of existing and new harm reduction practices to address the ongoing opioid crisis and substance use disorder more broadly. This FOA seeks applications focused on: (1) developing
and testing new harm reduction strategies; (2) examining how to effectively implement new and existing harm reduction strategies; (3) expanding the settings and delivery models through which harm reduction strategies are deployed; and (4) examining the impact
of new harm reduction policies implemented at state and local levels. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 10, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: February 28.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Research on Current Topics in Alzheimer’s Disease and Its Related Dementias (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-093.html" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements (FOAs) is to invite applications proposing research on current topics in Alzheimer’s disease and its related dementias. Further information
on the high-priority topics of interest will be announced through a series of Notices published subsequent to these FOAs.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 11, 2022; July 8, 2022; November 14, 2022; March 10, 2023; July 10, 2023; November 13, 2023; March 11, 2024; July 9, 2024; and November 12, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for March 11, 2022 due date: February 28.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Social disconnection and Suicide Risk in Late Life (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-136.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-135.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these FOAs is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest
is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not
limited to neurobiological, behavioral, and environmental.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 15, 2022 and October 15, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for March 15, 2022 due date: March 2.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.pfizer.com/purpose/independent-grants/investigator-sponsored-research" target="_blank">Pfizer Oncology Investigator Sponsored Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Qualified researchers are invited to submit investigator-sponsored research (ISR) proposals, according to the guidance and instructions found on the Pfizer ISR portal at <a href="https://click.icptrack.com/icp/relay.php?r=42347514&msgid=229405&act=K26I&c=1552564&destination=http%3A%2F%2Fwww.pfizer.com%2FISR&cf=13590&v=cafb85a154fc994c52cdc1ad29285b4d6ee71304eea5819204dec62220c98b38" target="_blank">www.Pfizer.com/ISR</a>. All
proposals must be submitted via the ISR submission portal. An ISR proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for ISR submissions are made by the
applicable Pfizer Global Review Committee. A formal notification regarding the status of your application will be sent on or before the posted notification date. Pfizer support will only be extended upon the execution of an ISR agreement. For any questions,
please send an email to <a href="mailto:GlobalMedicalGrants@pfizer.com" target="_blank">GlobalMedicalGrants@pfizer.com</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">A list of Oncology assets available for ISR proposals, including Areas of Interest, are available at
<a href="https://www.pfizer.com/about/programs-policies/grants/investigator-sponsored-research/oncology">
https://www.pfizer.com/about/programs-policies/grants/investigator-sponsored-research/oncology</a>. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due March 31, 2022; May 31, 2022; August 31, 2022; and January 5, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for March 31, 2022 due date: March 21.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Advancing communication strategies to support future HIV vaccine use (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-171.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-170.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Funding Opportunity Announcements invite applications for Research Project Grants that will advance novel health communication research designed to inform and support acceptance
and uptake of future vaccines that protect against HIV. Research should focus on understanding key drivers for HIV vaccine communication success, communication strategies for engagement of communities placed at greatest risk for acquiring HIV, and/or mitigating
the impact and reach of HIV vaccine misinformation. Research applications may leverage HIV vaccine analogs (e.g., COVID-19, HPV, HBV vaccines), so long as they have a primary focus on populations placed at risk for HIV, and/or healthcare settings and providers
involved in HIV prevention delivery.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due May 10, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: April 27.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">NIH S10s: Basic Instrumentation Grant (BIG) Program, High-End Instrumentation (HEI) Grant Program, Shared Instrument Grant (SIG) Program<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-081.html">BIG</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument
or an integrated instrumentation system.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The BIG Program is limited to institutions that have not received S10 instrumentation funding of $250,001 or greater in any of the preceding 3 Federal fiscal years (FY). Use the following
to determine applicable funding periods:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">for application due date of June 1, 2022, consider S10 funding in FYs 2019-2021;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">for application due date of June 1, 2023, consider S10 funding in FYs 2020-2022;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">for application due date of June 3, 2024, consider S10 funding in FYs 2021-2023.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The minimum award is $25,000. There is no maximum price limit for the instrument; however, the maximum award is $250,000. Instruments supported include, but are not limited to, basic cell
sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-079.html" target="_blank">HEI</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially
available instruments or integrated systems. The minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Instruments supported include, but are not limited to, X-ray diffractometers, high throughput
robotic screening systems, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-080.html">SIG</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially
available instruments or integrated instrumentation system. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000. Instruments supported include, but are not limited to: X-ray diffractometers,
mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 1, 2022 (FSU is eligible for BIG in 2022); June 1, 2023; and June 3, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for June 1, 2022 due date: May 18 (due to Memorial Day holiday).</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-061.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-062.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of these Funding Opportunity Announcements is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses,
and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent
inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter their effectiveness and thus those parameters should be rigorously addressed in the application.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">S<b>tandard dates apply. Expires January 8, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2022 standard date: May 23; and June 16 standard date: June 3.</span></b><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-358.html">Risk and Protective Factors of Family Health and Family Level Interventions (R01 – Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this initiative is to advance the science of minority health and health disparities by supporting research on family health and well-being and resilience. The NIMHD Research
Framework recognizes family health, family well-being, and family resilience as critically important areas of research to decrease disparities and promote equity.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for June 5, 2022 standard date: May 23.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-009.html">Lipids in Brain Aging and Alzheimer’s Disease (AD) and its Related Dementias (ADRD) (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of this Funding Opportunity Announcement is to support research addressing critical knowledge gaps in our understanding of how lipids contribute to vulnerability and resilience
to brain aging and Alzheimer’s disease (AD) and its related dementias (ADRD), including research addressing how: 1) lipid droplets affect brain aging and AD, including whether their accumulation is pathological or protective; (2) the periphery interacts with
lipids in the aging brain, including whether these could be targets for future biomarkers; (3) APOE and lipid-mediated signaling influence brain aging and AD/ADRD progression; and (4) myelin lipids and their signaling contribute to brain aging and AD/ADRD.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 14, 2022.
<span style="color:red">Med-RA deadline to receive draft documents: June 1.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69">CoM’s
unofficial funding opportunities blog</a>.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
</div>
</body>
</html>